Reciprocal tariffs may make Indian generic drugs costlier in US: Pharma giants on Trump stance

Indian pharmaceutical industry leaders indicate that proposed US tariffs on pharmaceutical exports may lead to increased drug costs and potential shortages in the US. They argue that the tariffs might be absorbed by consumers and stress the significant cost savings that affordable Indian generics provide to the US healthcare system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XkgjyJr
via IFTTT